CTLA4 and digestive system disorder: The onset of skin and gastrointestinal disorders induced by anti‐CTLA‐4 monotherapy tends to be earlier than that induced by anti‐PD‐1 monotherapy, such as within the first 3–5 weeks of treatment.32